Business Context and Reporting Period
This Form 8-K is a current report filed by Landec Corporation (not Lifecore Biomedical, Inc.) on October 16, 2018, covering events occurring on October 12, 2018. The filing details the entry into a new Indemnification Agreement and the results of the Annual Meeting of Stockholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on corporate governance and legal agreements.
Material Changes and Corporate Actions
- Indemnification Agreement: The Board of Directors approved a new form of Indemnification Agreement effective October 12, 2018, to replace the existing agreement for directors and executive officers. This agreement supplements rights under the certificate of incorporation and bylaws, covering expenses, judgments, fines, and settlements incurred during service.
- Annual Meeting Results: The company held its Annual Meeting on October 12, 2018, with the following outcomes:
- Director Elections: Five Class 1 directors were elected. All received significant majority support, with votes withheld ranging from approximately 305,000 to 1.36 million.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending May 26, 2019 (26,228,903 votes for vs. 229,860 against).
- Executive Compensation: Stockholders approved the non-binding advisory vote on executive compensation (23,264,424 votes for vs. 394,918 against).
Guidance, Outlook, and Risks
The filing does not provide financial guidance, future outlook, or management commentary on business strategy. The primary risk disclosure relates to the legal framework of the new Indemnification Agreement, which is qualified in its entirety by reference to the full agreement attached as Exhibit 10.1.
Investor Verification Checklist
- Verify the full text of the new Indemnification Agreement (Exhibit 10.1) to understand specific limitations and procedures for expense advancement.
- Confirm the composition of the newly elected Board of Directors and their tenure.
- Review the company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K contains none.
- Note the fiscal year end date of May 26, 2019, for future reporting cycle alignment.